Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 359

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 359
---
 |     |      |         |   |
| Cash                                                                        |     | $                        |     634 |   |     | $    |   5,783 |   |
| Restricted cash                                                             |     |                          |       4 |   |     |      |      75 |   |
| Total cash and restricted cash                                              |     | $                        |     638 |   |     | $    |   5,858 |   |
| Supplemental disclosure of cash flow information:                           |     |                          |         |   |     |      |         |   |
| Cash paid for interest                                                      |     | $                        |      23 |   |     | $    |      48 |   |
| Supplemental disclosure of noncash investing and financing activities:      |     |                          |         |   |     |      |         |   |
| Withholding to cover taxes from RSU vesting                                 |     | $                        |       — |   |     | $    |      69 |   |

See the accompanying notes to the consolidated financial statements. F-116

<div align='center'>**KINETA, INC.

Notes to Consolidated Financial Statements**</div>

**1. Organization and Liquidity

Description of Business

Kineta, Inc. (formerly Yumanity Therapeutics, Inc.) (together with its subsidiaries, the “Company”) is headquartered in Seattle, Washington.

The Company is a clinical stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance. Kineta Chronic Pain, LLC (“KCP”) was formed to develop new innovative therapies for pain management. Kineta Viral Hemorrhagic Fever, LLC (“KVHF”) was formed to develop a direct acting anti-viral therapy for the treatment of emerging diseases.

On November 30, 2023, the Company dissolved KVHF and assumed all of the outstanding issued equity. As of December 31, 2024, the Company owns a majority interest of the outstanding issued equity of KCP.

On February 29, 2024, Kineta announced that it had completed a review of its business, including the status of its programs, resources and capabilities. Following this review, Kineta determined that it would implement a significant corporate restructuring to substantially reduce expenses and preserve cash. The restructuring